Key Facts on Absci Corp.’s Drug Discovery Approach
Absci Corp. (NASDAQ: ABSI) utilizes generative AI for the design of protein drugs, leveraging its Integrated Drug Creation platform to transition from disease targets to potential drug candidates without extensive lab testing. The company partners with major organizations, including Merck and Owkin, to validate its AI-driven methodology. Absci aims to create breakthroughs in drug development, focusing on biologic drug candidates while also maintaining a pipeline of in-house programs.
In 2023, Absci entered a strategic R&D partnership with PrecisionLife, connecting AI drug design with computational patient stratification. The long-term outlook for Absci hinges on the success of its clinical programs and potential royalties from its innovations. However, challenges in drug discovery remain, and the company may need to issue more shares to fund operations.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
